Live
10x Genomics News10x Genomics (TXG) awards director Kimberly Popovits 8,829 RSUs - Stock Titan10x Genomics News10x Genomics (TXG) director receives 8,829 RSU grant, lifts holdings - Stock Titan10x Genomics News10x Genomics shareholders elect directors and approve proposals at annual meeting - Investing.com10x Genomics Blog10x Genomics shareholders elect directors and approve proposals at annual meeting - Investing.com10x Genomics Blog10x Genomics (NASDAQ: TXG) investors approve full 2026 meeting agenda - Stock TitanFierceBiotechCity aims to lay foundation for RNAi renaissance with nearly $100M series BEli LillyBig Pharma Stock Eli Lilly Concocts New Buy Zone - Investor's Business DailyEndpoints News#ADA26: AstraZeneca GLP-1 pill cuts weight 10.5% after six monthsVertexKyverna vs. Vertex: Clinical-Stage Risk vs. Cash-Flow Stability in Biotech Investing - News and Statistics - IndexBoxRoche MediaRoche and Nurix Therapeutics Announce Global Collaboration | PharmExec - Pharmaceutical ExecutiveBioPharma DiveCity banks nearly $100M for next-gen RNAi drugsEli LillyWith ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race - Fierce Pharma
BioWorld Dec 16, 2025

Hangzhou Baicreat Pharma-Tech describes new PTPN1 and PTPN2 inhibitors

Hangzhou Baicreat Pharma-Tech describes new PTPN1 and PTPN2 inhibitors

Original
Body unavailable. Use the original source.